Form 4: KALA BIO Executive Sells Shares to Cover Tax Obligations Under Pre-Arranged Plan

KALA BIO's Head of R&D and Chief Medical Officer, Romulus K Brazzell, sold 3,687 shares of common stock on June 3, 2025, at a weighted average price of $3.74, as part of a pre-arranged 10b5-1 plan to cover tax withholding obligations.

Summary

• Romulus K Brazzell, Head of Research and Development and Chief Medical Officer of KALA BIO, Inc., reported a sale of common stock.
• The transaction occurred on June 3, 2025.
• A total of 3,687 shares of common stock were disposed of.
• The weighted average sale price was $3.74 per share, with individual transactions ranging from $3.52 to $4.05.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Brazzell on November 9, 2020.
• The primary purpose of the sale was to cover tax withholding obligations associated with the vesting and settlement of restricted stock units (RSUs) granted on May 31, 2023.
• Following this transaction, Mr. Brazzell beneficially owns 87,949 shares of KALA BIO common stock, which includes 52,402 unvested RSUs.

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale to cover tax obligations related to RSU vesting, indicating a planned compensation event rather than a discretionary sale based on new information about the company's performance. This is generally neutral to slightly positive as it reflects executive compensation.

Positives

• The sale was made pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than a discretionary sale based on new, potentially negative, information.
• The sale was specifically to cover tax withholding obligations related to the vesting of restricted stock units (RSUs), which implies the executive received equity compensation as part of their remuneration.

Negatives

• An insider sale, even for tax purposes, reduces the executive's direct equity stake in the company.

Future Outlook

NA

Management Comments

• "This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ('RSUs') granted on May 31, 2023."

Industry Context

NA

Related Party Transactions

• Sale of 3,687 shares of common stock by Romulus K Brazzell, an officer of KALA BIO, Inc., to cover tax withholding obligations related to the vesting of his restricted stock units.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in an executive's direct equity stake, but as a pre-planned, tax-related transaction, it is unlikely to signal negative sentiment or significantly impact share price.
• Employees: The vesting of RSUs and subsequent tax-related sale is a standard component of executive compensation, which can be viewed as a positive for executive retention and motivation within the company.

Key Dates

Recommendation

Keywords

KALA BIO, KALA, Romulus K Brazzell, Form 4, insider trading, stock sale, restricted stock units, RSU, 10b5-1 plan, tax withholding, executive compensation